SCHEMBL22609343

SCHEMBL22609343

Cc1n[nH]c(C(=O)O)c1Nc1ccc(CCc2ccc(F)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ P4HTM Q9NXG6 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ GAA P10253 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ EGFR P00533 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ LMNA P02545 4/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ KCNH3 Q9ULD8 1/20 0.36
▸ DHODH Q02127 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23453709 0.82 P4HTM (0.47) P4HTMMEN1KMT2ALMNANPC1
SCHEMBL23486293 0.80 HAO2 (0.44) P4HTMSMN1; SMN2DHODHNPC1RAB9A
SCHEMBL22609257 0.72 ALDH1A1 (0.44) P4HTMSMN1; SMN2GAAMEN1KMT2A
SCHEMBL23453740 0.70 TAS2R14 (0.39) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL23453719 0.68 POLB (0.52) SMN1; SMN2MEN1KMT2ALMNAALDH1A1
SCHEMBL22609314 0.67 TAS2R14 (0.42) GAALMNAALDH1A1DHODH
SCHEMBL22609335 0.66 HTT (0.45) GAAMEN1KMT2ALMNAALDH1A1
SCHEMBL4218669 0.66 AKR1C3 (0.55) SMN1; SMN2GAAMEN1KMT2ATDP1
SCHEMBL1149649 0.65 DAO (0.42) EGFRCDK2
SCHEMBL4221805 0.65 MEN1 (0.56) MEN1KMT2ACDK2TDP1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS P4HTM 1453/4885SMN1; SMN2 4815/4885GAA 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback